LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fenwal Inc., a global medical technology company focused on improving blood separation, collection, safety and availability, announced today it has received clearances from the U.S. Food and Drug Administration to market the Fenwal Amicus® separator and Fenwal DXTTM Relay productivity software for paperless documentation and remote procedure set-up. Together, the blood-separation system and new software are designed to help blood collectors improve efficiency and meet regulatory compliance.
